Mahendra Rao From NIH to Present at the Stem Cell Summit 2013 (Apr 29-30, 2013 in Boston, MA)

Monrovia, CA (PressExposure) March 01, 2013 -- Mahendra Rao, Director of Center for Regenerative Medicine at the National Institutes of Health, will give a presentation on "Using PSC Derived Cells for Therapy" at the Stem Cell Summit 2013 (Apr 29-30, 2013 in Boston, MA).

Pluripotent cell therapy can be envisaged in a variety of ways and allogeneic therapy using completely mismatched samples can be performed. Matched samples can be used or truly personalized medicine where an individual's own cells can be differentiated appropriately to generate cells that can be transplanted without the need for immune suppression. Cells can be engineered as delivery vehicles to provide replacement therapy or to augment endogenous repair processes. The NIH Center of Regenerative Medicine developed methods to enable each of these processes and will discuss sourcing and manufacturing issues. In addition, Dr. Rao will describe recent advances in direct differentiation which may open up avenues to perform in vivo therapy.

Dr. Mahendra Rao is internationally renowned for his research involving human embryonic stem cells (hESCs) and other somatic stem cells. He has worked in the stem cell field for more than 20 years, with stints in academia, government and regulatory affairs and industry. Most recently, he spent six years as the vice president of Regenerative Medicine at Life Technologies in Carlsbad, California. He co-founded Q Therapeutics, a neural stem cell company based in Salt Lake City, Utah. He also served internationally on advisory boards for companies involved in stem cell processing and therapy; on committees, including as the U.S. Food and Drug Administration's Cellular Tissue and Gene Therapies Advisory Committee chair; and as the California Institute of Regenerative Medicine and International Society for Stem Cell Research liaison to the International Society for Cellular Therapy.

The 2013 Stem Cell Summit includes two parallel tracks including joint sessions. This summit provides cutting-edge information on developments in all areas of stem cell research including the biology, medicine, applications, regulations, and commercialization of stem cells.

Track A: Stem Cell Research & Regenerative Medicine:
Joint Session: Funding Opportunities
Joint Session: Regulatory Guidance & Updates
Session: Advances in iPS & ES Cells
Session: Advances in Adult Stem Cells
Session: New Paradigms for Cell Therapy

Track B: Stem Cell Commercialization & Partnering:
Joint Session: Funding Opportunities
Joint Session: Regulatory Guidance & Update
Session: Novel Technologies in Stem Cell Research
Session: Overcoming Challenges in Clinical Development
Session: Commercialization: Bringing Therapeutics to Market
Session: Partnerships & Acquisitions

Summit Agenda: http://www.gtcbio.com/stemcellsummit/agenda
Summit Speaker List: http://www.gtcbio.com/stemcellsummit/speakers
For more information, please visit http://www.gtcbio.com

About GTCbio

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.


GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source: http://PressExposure.com/PR/GTCbio.html

Press Release Submitted On: March 01, 2013 at 1:23 am
This article has been viewed 29076 time(s).